Activated Probiotics New Product Launches
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
30 April, 2025
Activated Probiotics New Product Launches
● Biome to release two new Products into the Activated Probiotics range in
Q4 FY25
● Biome Her™ Pessary
○ Featuring a clinically-trialled combination of probiotic strains shown
to support healthy vaginal microbiome balance1
● Biome Perinatal™ Probiotic
○ Featuring a clinically-trialled probiotic strain shown to support
healthy pregnancy outcomes and improve postpartum mood
balance2-5
Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the
company’) is pleased to provide an update on two new product launches
supporting women's health through our flagship brand, Activated Probiotics.
Women’s health is the number one vitamin and dietary supplements category by
sales volume in Australia6. With over 75% of Australian households using
complementary medicines6, demand for female-focused products– including
those targeting vaginal health, fertility, pregnancy, and overall well-being–
continues to rise. Female customers and patients are the leading demographic of
complementary medicine consumers, often being the main purchaser of
probiotics and complementary medicines. With two new product offerings,
Biome is aiming to better support this demographic at earlier life stages and
through their child-bearing years.
Biome Her™ Pessary
Biome Her™ Pessary will complement Biome Her™ Probiotic, an oral probiotic
for vaginal microbiome balance, by providing targeted support through a new
vaginally-inserted probiotic pessary. This product includes clinically-trialled
probiotic strains1 and will include 10 vaginal capsules designed to be
recommended for short-term use to women with acute vaginal health concerns,
and has been listed on the Australian Register of Therapeutic Goods to
maintain/support vaginal healthy flora/microflora.
Biome Perinatal™ Probiotic
Biome has also identified an opportunity in the Australian and international
markets for a high-quality evidence-based probiotic for use before, during and
after pregnancy including throughout breastfeeding.
Biome Perinatal+ Probiotic, Biome’s upcoming offering in this category, includes
clinically-trialled probiotic strains which have demonstrated clinical evidence of
efficacy for their ability to support the health needs of women before, during and
after pregnancy2-5,, and has been listed on the Australian Register of Therapeutic
Goods with the following health claims:
-
-
-
-
Maintain/support healthy pregnancy
Helps enhance/promote maternal health
Helps enhance/promote maternal postnatal health
Support healthy emotional/mood balance in post-partum women
Alongside women’s products being number one in the industry, there were $98.6
million prenatal multivitamin supplement sales in 2024, a key co-prescribing
opportunity for Biome Perinatal™ Probiotic.6
Lactobacillus acidophilus LA02 and Lactobacillus fermentum LF10
Biome has worked with its research partners to identify key probiotic strains that
have been found in human clinical trials to support vaginal microbiota balance. In
women with recurrent vaginal thrush, Lactobacillus acidophilus LA02 and
Lactobacillus fermentum LF10 have been found to reduce relapse rates to 27.6%
when administered after standard treatment1. Current standard treatment
approaches alone are not particularly effective, with post-treatment relapse rates
as high as 57%7.
Lactobacillus rhamnosus HN001
Similarly, probiotic strains which help to improve health outcomes during
pregnancy and into motherhood have also been an area of focus. Lactobacillus
rhamnosus HN001 is one such strain that was identified as a well-researched
probiotic intervention indicated for this application, with reductions in the rate of
gestational diabetes5, improved postpartum mood balance2, and protection
against eczema development4 in future children* observed when supplemented
during pregnancy and throughout breastfeeding (*when the children were also
supplemented with this probiotic strain in the first two years of life).
References
1.
2.
3.
4.
5.
6.
7.
Murina F, Graziottin A, Vicariotto F, De Seta F. Can Lactobacillus fermentum LF10 and Lactobacillus
acidophilus LA02 in a slow-release vaginal product be useful for prevention of recurrent vulvovaginal
candidiasis?: A clinical study. J Clin Gastroenterol. 2014;48(December):S102–5.
Slykerman, R. F., Hood, F., Wickens, K., Thompson, J. M. D., Barthow, C., Murphy, R., ... & Mitchell, E. A.
(2017). Effect of Lactobacillus rhamnosus HN001 in pregnancy on postpartum symptoms of depression
and anxiety: a randomised double-blind placebo-controlled trial. EBioMedicine, 24, 159-165.
Kalliomäki, M, Salminen, S, Poussa, T, et al. (2007) Probiotics during the first 7 years of life: a cumulative
risk reduction of eczema in a randomised, placebo-controlled trial. J Allergy Clin Immunol 119, 1019–1021.
Wickens, K., Black, P. N., Stanley, T. V., Mitchell, E., Fitzharris, P., Tannock, G. W., ... & Probiotic Study Group.
(2008). A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind,
randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology, 122(4), 788-794.
Wickens, K. L., Barthow, C. A., Murphy, R., Abels, P. R., Maude, R. M., Stone, P. R., ... & Crane, J. (2017). Early
pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence
of gestational diabetes mellitus: a randomised controlled trial. British Journal of Nutrition, 117(6),
804-813.
Complementary Medicines Australia. (2024). 2024 Industry Snapshot. Available from:
https://cmaustralia.org.au/wp-content/uploads/CMA-Snapshot-2024.pdf
Bradfield Strydom M, Walpola RL, Khan S, Ware RS, Tiralongo E. Evidence-based update on Australasian
pharmaceutical prescribing approaches for recurrent vulvovaginal candidiasis. Aust N Z J Obstet
Gynaecol. 2021 Aug;61(4):496-499.
Activated Probiotics
Probiotics®
Practitioner-only probiotics
Women’s Health
Biome Her™
Pessary
Education Team Master Presentation
1
Activated Probiotics®
Practitioner-only probiotics
A new vaginal pessary to
support women re-establish a
healthy vaginal microbiome
Biome Her™ Pessary is more suitable for short-term use for
women with acute vaginal health concerns, and includes
clinically trialled probiotic strains that help women re-establish
and maintain a healthy vaginal microbiome.
NPD Presentation
2
Activated Probiotics®
Practitioner-only probiotics
Practitioner-only product
Biome Her™ Pessary
●
To help maintain a healthy vaginal microbiome
Formulation
Education Team Master Presentation
Lactobacillus crispatus LCR01 (DSM 24619)
1 BLB*
Lactobacillus fermentum LF10 (DSM 19187)
1 BLB*
Lactobacillus acidophilus LA02 (DSM 21717)
1 BLB*
Total live bacteria
3 BLB*
3
Activated Probiotics®
Practitioner-only probiotics
Biome Her™ Pessary
Market analysis
The global women's probiotic market is growing at a compound
annual growth rate (CAGR) of 18.1% from 2024 to 2034.
The women's probiotic market in Australia and New Zealand is
projected to grow at a CAGR of 8.2% from 2024 to 2034.1
Women’s
health is the
#1 dietary
supplements
category by
sales volume
in Australia2
With over 75% of Australian households using complementary
medicines, demand for female-focused products—including
those targeting vaginal, fertility and pregnancy—continues to
rise.2
1. Future Market Insights. (2024). Women’s Probiotic Market Report. Retrieved from
https://www.futuremarketinsights.com/reports/women-probiotic-market
2. Complementary Medicines Australia. (2024). CMA Snapshot 2024. Retrieved from
https://cmaustralia.org.au/wp-content/uploads/CMA-Snapshot-2024.pdf
NPD Presentation
4
Activated Probiotics®
Practitioner-only probiotics
Biome Her™ Pessary
Consumer needs
Approximately 70% of women will develop vaginal thrush in
their lifetime
Recurrent vaginal thrush affects up to 10% of Australian
women1
Probiotic strains
LA02 and LF10
reduced
relapse rates
to 27.6%
when used after
standard
treatment2
NPD Presentation
It has debilitating effects on the physical and emotional
well-being of these women1
Standard treatment is not particularly effective with
post-treatment relapse rates as high as 57%1
1. Bradfield Strydom M, Walpola RL, Khan S, Ware RS, Tiralongo E.
Evidence-based update on Australasian pharmaceutical prescribing
approaches for recurrent vulvovaginal candidiasis. Aust N Z J Obstet
Gynaecol. 2021 Aug;61(4):496-499.
2. Murina F, Graziottin A, Vicariotto F, De Seta F. Can Lactobacillus fermentum
LF10 and Lactobacillus acidophilus LA02 in a slow-release vaginal product be
useful for prevention of recurrent vulvovaginal candidiasis?: A clinical study.
J Clin Gastroenterol. 2014;48(December):S102‒5.
5
Activated Probiotics
Probiotics®
Practitioner-only probiotics
Women’s Health
Biome Perinatal™
Probiotic
NPD Presentation
6
Activated Probiotics®
Practitioner-only probiotics
Practitioner-only product
Biome Perinatal™ Probiotic
●
●
●
Supports a healthy pregnancy
Helps promote maternal health
Supports healthy postpartum mood balance
Formulation
Lactobacillus rhamnosus GG (ATCC 53103)
5 BLB*
Lactobacillus rhamnosus HN001 (ATCC SD5675)
6 BLB*
Lactobacillus crispatus LCR01 (DSM 24619)
1 BLB*
Bifidobacterium breve BR03 (DSM 16604)
5 BLB*
Bifidobacterium animalis subsp. lactis BA05 (DSM 18352)
3 BLB*
Total live bacteria (BLB=Billion Live Bacteria)
NPD Presentation
20 BLB*
7
Activated Probiotics®
Practitioner-only probiotics
A new probiotic formulation
to support women before,
during and after their
pregnancy journey
Biome Perinatal™ is formulated with clinically-trialled probiotic
strains that have evidence to support a healthy pregnancy,
promote maternal health and support healthy postpartum mood
balance.
NPD Presentation
8
Activated Probiotics®
Practitioner-only probiotics
Biome Perinatal™ Probiotic
Market analysis
According to the Australian Institute of Health and Welfare, there
were nearly 300,000 pregnant women in Australia in 20221.
Biome Perinatal™ offers targeted probiotic support to this group
of women prior to, during and in the one year period following
their pregnancy journey, compounding into a total market size of
approximately 1 million+.
$98.6 million
prenatal
multivitamin
supplement
sales in 20242
Biome Perinatal™ offers a streamlined co-prescribing
opportunity for the highly engaged customer purchasing
prenatal supplements.
1. Australian Institute of Health and Welfare. (2024). Australia's mothers and
babies: State and territory. Retrieved from
https://www.aihw.gov.au/reports/mothers-babies/australias-mothers-babies/co
ntents/overview-and-demographics/state-and-territory
2. Complementary Medicines Australia. (2024). CMA Snapshot 2024. Retrieved
from https://cmaustralia.org.au/wp-content/uploads/CMA-Snapshot-2024.pdf
NPD Presentation
9
–ENDS–
Approved for release by the Biome Australia board of directors.
Investor Hub
Biome has launched a new interactive investor hub. To view a video presentation of this
announcement, ask questions or sign up for future company updates, please visit the
investor hub via this link (https://investorhub.biomeaustralia.com/).
About Biome Australia Limited
Biome Australia develops, licenses, commercialises and markets innovative,
evidence-based live biotherapeutics (probiotics) and complementary medicines, many of
which are supported by clinical research. Biome aims to improve health outcomes and
quality of life, and make its products accessible to all.
Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with
some of the world's leading organisations in microbiome research and development,
Biome produced several unique live biotherapeutic (probiotic) products with innovative
delivery technologies that improve their stability and efficacy to create its flagship range
®
of complementary medicines: Activated Probiotics .
Supported by clinical research, including randomised double-blind placebo-controlled
trials, Activated Probiotics help prevent and support the management of various health
concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema
and IBS. Through practitioner-only distribution, Biome is committed to educating health
professionals on the newfound systemic health effects of the gut microbiota, helping
them to provide innovative, evidence-based natural medicines for the management of
some of humanity's most prevalent and chronic health concerns.
Biome also develops, licenses and distributes a scientifically formulated, organic
®
nutraceutical range, Activated Nutrients .
For more information visit: www.biomeaustralia.com
Investor Relations
Rechelle Friend
corporate@biomeaustralia.com
(03) 9017 5800
Forward looking statements
This release may contain forward looking statements, including but not limited to projections,
guidance on future revenues, earnings, other potential synergies and estimates and the future
performance of Biome (Forward Looking Statements).
Forward Looking Statements are provided as a general guide only and should not be relied upon
as an indication or guarantee of future performance. Actual results, performance or achievements
may differ materially from those expressed or implied in such Forward Looking Statements and
any projections and assumptions on which these Forward Looking Statements are based. Such
statements may assume the success of Biome's business strategies. You are cautioned not to
place undue reliance on Forward Looking Statements.
The Forward Looking Statements are based on information available to Biome as at the date of
this release. Any Forward Looking Statements containing forward looking financial information
provided in this release is for illustrative purposes only and is not represented as being indicative of
Biome's views on its future financial condition and/or performance.
Nothing in this release is a promise or representation as to the future. No representation or
warranty, express or implied, is made as to the accuracy, likelihood of achievement or
reasonableness of any Forward Looking Statements contained in this release. Except as required
by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any
additional or updated information whether as a result of a change in expectations or assumptions,
new information, future events or results or otherwise.
To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in
respect of, and makes no representation or warranty, express or implied as to the fairness,
currency, accuracy, reliability or completeness of information in this release or the accuracy,
likelihood of achievement or reasonableness of any Forward Looking Statements (or any event or
results expressed or implied in any Forward Looking Statements) contained in, implied by, the
information in this release or any part of it, or that this release contains all material information
about Biome or which a prospective investor or purchaser may require in evaluating a possible
investment in Biome or acquisition of securities in Biome.
Investors are strongly cautioned not to place undue reliance on Forward Looking Statements,
particularly in light of the current economic climate and the significant volatility, uncertainty and
disruption caused by the Covid-19 pandemic.
Share your feedback
Discover